Tirzepatide Cost: Every Price Tier Explained

Tirzepatide price table: channel and dose

Unlike semaglutide's flat $499 self-pay structure, tirzepatide pricing shifts with dose on the vial program. The current grid:

LillyDirect vials require drawing the dose with a syringe rather than using a pen. Insurance copay assumes a plan covering Zepbound, which frequently requires prior authorization.

Zepbound vs Mounjaro: same molecule, different price logic

Both brands are tirzepatide at identical doses, 2.5 mg through 15 mg weekly. The $17 gap in list price is trivial; what matters is indication. Zepbound is approved for weight loss and for obstructive sleep apnea, so weight-focused coverage and the LillyDirect cash program attach to it. Mounjaro is approved for type 2 diabetes, where insurance coverage is far more reliable and a manufacturer savings card can cut copays for commercially insured patients.

The practical consequence: diabetics usually pay less through Mounjaro and its coverage path, while weight loss patients get their best cash price through Zepbound vials. Paying list price for either, $13,032 a year for Zepbound, only happens when someone misses the direct-purchase programs entirely.

Insurance treatment splits along the same line: Zepbound claims are judged against weight management or sleep apnea criteria, Mounjaro claims against diabetes criteria, and submitting the wrong brand for the wrong diagnosis is one of the most common self-inflicted denials in the category. Getting the pairing right costs nothing and can be worth over $12,000 a year.

LillyDirect vials: brand tirzepatide from $349

Lilly's answer to cash-pay demand is selling Zepbound as single-dose vials through LillyDirect at $349 a month for 2.5 mg and $499 for 5 mg and higher. It is authentic, FDA-approved tirzepatide at roughly a third of pen list price.

The trade-offs are concrete. You draw each weekly dose with a needle and syringe instead of clicking a pen. The $349 tier only covers the 2.5 mg starting dose, which trial protocol uses for the first four weeks, so most people budget at $499 from month two onward. And it is strictly self-pay: the program cannot be combined with insurance. For a full first year following standard titration, that is roughly $4,188 to $5,988, against $13,032 at list.

Compounded tirzepatide at $199–$449: what changed

Compounded tirzepatide occupies the $199–$449 band, and its rules tightened before semaglutide's did. The FDA declared the tirzepatide shortage resolved in December 2024, closing the period when 503A pharmacies could produce straightforward copies at scale. Today, access runs through personalized formulations prescribed via telehealth, with availability more restricted and more variable between programs.

Price inside the band tracks dose: entry-level doses near $199, higher maintenance doses toward $449, which narrows the gap with LillyDirect's $499 brand vials at exactly the doses most people stay on. That convergence is the key 2026 dynamic; the cheapest tirzepatide breakdown runs the head-to-head math tier by tier. To see what personalized programs currently charge for your target dose, compare tirzepatide telehealth pricing here.

What a year of tirzepatide actually costs

Tirzepatide titrates from 2.5 mg to as high as 15 mg over several months, and SURMOUNT-1's 20.9% average result was measured at 72 weeks. Realistic annual budgets by channel:

• Insurance with coverage: $300–$600 a year, prior authorization permitting.
• Compounded telehealth: roughly $2,388–$5,388 a year, dose-dependent.
• LillyDirect vials: about $5,700 for year one with one month at $349, then $499.
• Retail pens at list: $12,828–$13,032, the price of never checking the alternatives.

The dose schedule is what makes tirzepatide budgeting different from semaglutide's. Standard titration holds 2.5 mg for about four weeks, then steps through 5 mg and upward, with many people settling at 10 mg or 15 mg maintenance. On flat-priced channels this is irrelevant; on dose-priced compounded programs it means the monthly bill climbs during exactly the months your patience is being tested. Map a program's per-dose prices against the escalation schedule before committing, and treat any quoted entry price as a month-one number, not a plan price.

Run the composite honestly: a compounded plan that starts near the bottom of the $199–$449 band but reaches its top at maintenance doses lands somewhere between $3,000 and $4,800 for year one, against roughly $5,700 on LillyDirect and $12,800-plus at retail. The saving is real but smaller than entry pricing implies, which is why the maintenance-dose price, not the starter price, is the number to compare across programs. Add the small stuff on vial routes, syringes and sharps disposal, plus prescriber fees when they are not bundled.

Both direct and compounded routes are HSA/FSA eligible with a prescription. Whether tirzepatide's extra ~5–6 points of average weight loss over semaglutide justifies its higher floor is exactly the question our semaglutide vs tirzepatide comparison answers. Eligibility criteria are the same: BMI 30 or above, or 27 with a weight-related condition, confirmed by a licensed provider.